ArticleBioinformation2024
Dengue virus infection: potential applications of "Omics" based approaches.
Article in Bioinformation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue, caused by the dengue virus (DENV), a member of the flavivirus family, continues to pose a significant threat to populations worldwide, despite advances in technology. Nearly half of the global population is at risk of contracting the disease, ranging from mild dengue fever (DF) to severe dengue hemorrhagic fever (DHF) and Dengue Shock Syndrome (DSS). The precise mechanisms underlying the progression of DF to DHF and DSS remain unclear and the presence of various DENV serotypes exacerbates this situation. Urbanization and climate change are expected to affect dengue epidemiology, potentially increasing the frequency and intensity of outbreaks. This review aims to consolidate the current knowledge on the biological characteristics, pathogenesis and application of "Omics" based strategies for biomarker discovery for precision medicine. Although the precise mechanisms behind the progression from DF to DHF/DSS are not fully understood, hypotheses include immune over-activation, cytokine storms and antibody-dependent enhancement. Studies of comorbid conditions have shown no significant association with the development of DHF/DSS in patients with diabetes, hypertension, or other chronic diseases. Despite the far-reaching and intricate nature of dengue, the inconsistencies found in clinical pathophysiological studies underscore the need for additional research aimed at elucidating the pathogenesis of DHF/DSS and devising effective preventive measures. Identifying the differentially expressed genes, proteins and metabolites in DF, DHF and DSS may enrich our understanding of the mechanisms underlying their pathogenesis. Moreover, these differentially regulated pathways may serve as novel therapeutic targets. These biomarkers may also be utilized for disease surveillance and the evaluation of the efficacy of therapeutic interventions for personalized treatment. Continuous research is essential to gain deeper insights into the mechanisms and progression of dengue fever and to formulate more effective prevention and control strategies. A multidisciplinary approach is vital for comprehending dengue virus pathogenesis, identifying risk factors and creating targeted interventions, particularly through biomarker discovery using "Omics" approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.